Program
carfilzomib
Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.
Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 230 open or running | phase 4since Apr 16, 2019 | Sep 6, 2005 | none ahead |
| AbbVie | 32 open or running | phase 3since Nov 28, 2023 | Sep 27, 2013 | Jun 2027phase 2 · NCT02899052 |
| Criteriumits history only | 30 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Jan 3, 2013 | Jan 3, 2013 | none ahead |
| Sanofiits history only | 22 open or running | phase 2since Jan 20, 2023 | Jan 20, 2023 | Apr 1, 2027phase 2 · NCT06356571 |
Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2013First study: phase 2 study in Multiple MyelomaFirst studyNCT01962792 · 84 enrolled · United States, Canada
- Sep 1, 2016Phase 2 study in Multiple MyelomaNCT02899052 · 120 enrolled · United States, Australia, Hungary and more
- Nov 28, 2023Phase 3 study in Multiple MyelomaNCT06158841 · 421 enrolled · United States, Australia, Austria and more
Ahead
- Jun 2027Primary completion: phase 2 study in Multiple MyelomaNCT02899052
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06158841
TargetBeta
“26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 85 |
Studies
All 3 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Dec 2027 | 421 |
| NCT02899052Multiple Myeloma · United States, Australia, Hungary and more | 2 | Active, not recruiting | Jun 2027 | 120 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | Mar 2019 | 84 |
How it is read
Names in the registry
- “Carfilzomib”, 34 entries
- “carfilzomib”, 3 entries
- “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
- “Drug: Carfilzomib + Dexamethasone”, 1 entry
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 33 studies
- Amyloidosis, 1 study
- Small Cell Lung Carcinoma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.